Orexo announces that partner ProStrakan has presented strong sales figures for Abstral in Europe

Uppsala, January 7, 2010 – Orexo AB (STO: ORX) announces today that its partner ProStrakan Group plc (LSE: PSK) has presented its sales figures for Abstral in Europe in a press release. ProStrakan states that sales of Abstral underwent a strong development in 2009 and sales in the range of GBP 5 M – GBP 6 M were achieved for full-year. In ProStrakan’s press release from November 2009, it was stated that sales for the first ten months of 2009 amounted to GBP 3.2 M. Commenting on today’s announcement, Torbjörn Bjerke, Orexo’s President and CEO, said: “Abstral’s sales growth is very strong in Europe and we can see that there is a large medical need to be met for cancer patients suffering from breakthrough pain. The increasing royalties are important in developing Orexo into a profitable pharmaceutical company.” For further information, contact: Torbjörn Bjerke, President and CEO Tel: +46 (0)708-66 19 90 E-mail: torbjorn.bjerke@orexo.com Claes Wenthzel, Executive Vice President and CFO Tel: +46 (0)708-620 122 E-mail: claes.wenthzel@orexo.com About Abstral Abstral is a fast-dissolving tablet for sublingual administration of fentanyl, intended for the management of breakthrough cancer pain in patients who are already receiving opioid analgesics. It is based on Orexo’s unique and patented sublingual tablet technology in which a rapidly dissolving tablet is placed under the tongue and the active substance is absorbed by the mucous membrane. Currently Abstral is sold in Sweden, UK, Germany, Spain, Greece and France. An NDA for Abstral has been filed in the US by the partner ProStrakan and in Japan Abstral is being prepared for registration by the partner Kyowa Hakko Kirin. About Orexo Orexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. The company has four products on the market as well as a broad project portfolio in late stages of development. Sales and product development are mainly carried out through worldwide partnership agreements with larger pharmaceutical companies. Orexo has 126 employees, and has its head office located in Uppsala, Sweden. More information can be found at www.orexo.com. Note: This is information that Orexo AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act and/or the Swedish Securities Markets Act. The information was provided for public release on 7th January, 2010 at 12:40 CET.